News
MDWD
17.61
+0.11%
0.02
MediWound To Present New Data From EscharEx Phase II Studies At 3 Wound Care Conferences
Oral presentations include additional comparative data between EscharEx® and SANTYL®, and new analyses show strong correlation between wound bed preparation and wound healing Analyses validate the planned design and endpoints of the upcoming Phase III study. Clinical data will be presented throughout May 2024 at the largest annual meetings in the field of chronic wound care. Eschar ex is a bioactive, enzymatic debridement agent for the treatment of chronic wounds.
Benzinga · 10h ago
Weekly Report: what happened at MDWD last week (0415-0419)?
Weekly Report · 3d ago
Strength Seen in MediWound (MDWD): Can Its 14.3% Jump Turn into More Strength?
NASDAQ · 04/17 11:24
Weekly Report: what happened at MDWD last week (0408-0412)?
Weekly Report · 04/15 12:02
Weekly Report: what happened at MDWD last week (0401-0405)?
Weekly Report · 04/08 12:09
Weekly Report: what happened at MDWD last week (0325-0329)?
Weekly Report · 04/01 12:05
Analysts Are Bullish on Top Healthcare Stocks: Mediwound (MDWD), Ironwood Pharma (IRWD)
TipRanks · 03/28 17:30
Weekly Report: what happened at MDWD last week (0318-0322)?
Weekly Report · 03/25 12:09
Analysts Offer Insights on Healthcare Companies: Eledon Pharmaceuticals (ELDN), Medtronic (MDT) and Mediwound (MDWD)
TipRanks · 03/22 10:30
MediWound Price Target Maintained With a $28.00/Share by HC Wainwright & Co.
Dow Jones · 03/22 10:28
HC Wainwright & Co. Reiterates Buy on MediWound, Maintains $28 Price Target
Benzinga · 03/22 10:18
Mediwound Poised for Growth: A Strong Buy Recommendation Amidst Promising Prospects and Strategic Expansion
TipRanks · 03/21 22:55
MDWD Stock Earnings: MediWound Beats EPS, Beats Revenue for Q4 2023
MediWound reported earnings per share of -19 cents. The company reported revenue of $5.34 million. This was 0.34% better than the analyst estimate for the company to report revenue of -20 million. The stock was down 2.7% after the market closed.
Investorplace · 03/21 15:54
MediWound (MDWD) Reports Q4 Loss, Tops Revenue Estimates
NASDAQ · 03/21 12:25
MediWound Boasts Robust 2023 Financials and Growth
TipRanks · 03/21 11:57
MediWound Q4 EPS $(0.19) Beats $(0.23) Estimate, Sales $5.34M Beat $5.32M Estimate
MediWound reported quarterly losses of $0.19 per share and sales of $5.34 million. The company beat the analyst consensus estimate for quarterly losses by 17.39%. The company also reported a 54.05 percent decrease in sales from the same period last year.
Benzinga · 03/21 11:04
Earnings Scheduled For March 21, 2024
Creative Realities is expected to report quarterly earnings at $0.02 per share on revenue of $16.47 million. Welltower is likely to report earnings for its fourth quarter. Accenture is also projected to report before the bell. Other companies expected to be reporting before the Bell include Shoe Carnival, Y.M.C. And Y.T.
Benzinga · 03/21 10:15
MediWound: Q4 Earnings Snapshot
MediWound Ltd. Reports a loss of $1.7 million in its fourth quarter. The developer of treatments for burns and hard-to-heal wounds posted revenue of $5.3 million. The results exceeded Wall Street expectations. For the year, the company reported losses of $6.8 million.
Barchart · 03/21 06:25
MediWound Q4 2023 Earnings Preview
MediWound Ltd. Is scheduled to announce Q4 earnings results on Thursday, March 21st. The consensus EPS Estimate is -$0.21 and the consensus revenue estimate is $5.33M. Over the last 2 years, MDWD has beaten EPS estimates 25% and 75% of the time.
Seeking Alpha · 03/20 15:29
Weekly Report: what happened at MDWD last week (0311-0315)?
Weekly Report · 03/18 12:07
More
Webull provides a variety of real-time MDWD stock news. You can receive the latest news about Mediwound through multiple platforms. This information may help you make smarter investment decisions.
About MDWD
Mediwound Ltd is an Israel-based biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration. Company's portfolio is focused on next-generation protein-based therapies for burn and wound care and tissue repair and includes products such as, NexoBrid, a concentrate of proteolytic enzymes enriched in bromelain, which is an easy to use, topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues.; EscharEx biological drug candidate for the debridement of chronic and other hard-to-heal wounds; MW005 a topically applied biological drug candidate for the treatment of non-melanoma skin cancers, based on the same API of NexoBrid and EscharEx products, a concentrate of proteolytic enzymes enriched in bromelain.